MS-based, Quantitative Plasma Proteomics | Cambridge Isotope Laboratories, Inc.
This review article provides a retrospective and prospective five-year view of quantifying human plasma proteins for biomarker development in a clinical setting. The highlighted methods are categorized under a fit-for-purpose approach (i.e., from Tier 1 to Tier 3 for clinical and exploratory assays, respectively) and primarily utilize a bottom-up methodology with stable isotope-labeled standards (at the protein or peptide level) for quantification. Discussed are the challenges, requirements, and strategies for translating candidate protein biomarkers from research to the clinic.
Abstract
INTRODUCTION:
AREAS COVERED:
Percy AJ, Byrns S, Pennington SR, Holmes DT, Anderson NL, Agreste TM, Duffy MA.
Articles
- Determining Synthesis Rates of Individual Proteins in Zebrafish Danio rerio with Low Levels of a Stable Isotope Labelled Amino Acid
- NeuCode Proteomics and Bap1 Regulation of Metabolism | Cambridge Isotope Laboratories, Inc.
- Stable-Isotope Labeling of Algal Biomass Carbohydrates | Cambridge Isotope Laboratories, Inc.
- Biochemical Pathways Affected by Mitochondrial Stress | Cambridge Isotope Laboratories, Inc.
- MS-based, Quantitative Plasma Proteomics | Cambridge Isotope Laboratories, Inc.